Protein kinase molecules
AssigneeIncyte Pharmaceuticals, Inc.
InventorsOlga Bandman, Jennifer L. Hillman, Preeti Lal, Ingrid E. Akerblom, Purvi Shah, Neil C. Corley, Karl J. Guegler
Life of this patent
Estimating the term…
Loading patent…
AssigneeIncyte Pharmaceuticals, Inc.
InventorsOlga Bandman, Jennifer L. Hillman, Preeti Lal, Ingrid E. Akerblom, Purvi Shah, Neil C. Corley, Karl J. Guegler
Estimating the term…
The invention provides human protein kinase molecules (HPKM) and polynucleotides which identify and encode HPKM. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HPKM.
An isolated and purified polynucleotide sequence encoding a polynucleotide sequence comprising an amino acid sequence of SEQ ID NO:3.
An isolated and purified polynucleotide sequence consisting of a polynucleotide sequence of SEQ ID NO:9.
Dependencies are inferred from the claim text.
Drawings are temporarily unavailable. Open the PDF at USPTO
No references of this kind are recorded.
Transferring phosphorus containing groups, e.g. kinases: phosphotransferases with an alcohol group as acceptor , e.g. protein kinases
Medicinal preparations containing peptides
Microorganisms or enzymes
Medicines and medical preparations
Term ended 30 Jan 2018 (estimated)
USPTO file history isn’t available for this patent, so only indexed dates are shown.
This invention relates to nucleic acid and amino acid sequences of a protein kinase molecules and to the use of these sequences in the diagnosis, treatment, and prevention of cancer and immune disorders.
Kinases regulate many different cell proliferation, differentiation, and signaling processes by adding phosphate groups to proteins. Uncontrolled signaling has been implicated in a variety of disease conditions including inflammation, cancer, arteriosclerosis, and psoriasis. Reversible protein phosphorylation is the main strategy for controlling activities of eukaryotic cells. It is estimated that more than 1000 of the 10,000 proteins active in a typical mammalian cell are phosphorylated. The high energy phosphate which drives activation is generally transferred from adenosine triphosphate molecules (ATP) to a particular protein by protein kinases and removed from that protein by protein phosphatases. Phosphorylation occurs in response to extracellular signals (hormones, neurotransmitters, growth and differentiation factors, etc), cell cycle checkpoints, and environmental or nutritional stresses and is roughly analogous to turning on a molecular switch. When the switch goes on, the appropriate protein kinase activates a metabolic enzyme, regulatory protein, receptor, cytoskeletal protein, ion channel or pump, or transcription factor.
The kinases comprise the largest known protein group, a superfamily of enzymes with widely varied functions and specificities. They are usually named after their substrate, their regulatory molecules, or some aspect of a mutant phenotype. With regard to substrates, the protein kinases may be roughly divided into two groups; those that phosphorylate tyrosine residues (protein tyrosine kinases, PTK) and those that phosphorylate serine or threonine residues (serine/threonine kinases, STK). A few protein kinases have dual specificity and phosphorylate threonine and tyrosine residues. Almost all kinases contain a similar 250-300 amino acid catalytic domain. The N-terminal domain, which contains subdomains I-IV, generally folds into a two-lobed structure which binds and orients the ATP (or GTP) donor molecule. The larger C terminal lobe, which contains subdomains VI A-XI, binds the protein substrate and carries out the transfer of the gamma phosphate from ATP to the hydroxyl group of a serine, threonine, or tyrosine residue. Subdomain V spans the two lobes.
The examples below are provided to illustrate the subject invention and are not included for the purpose of limiting the invention.
For purposes of example, the preparation and sequencing of the OVARNOT03 cDNA library, from which Incyte Clone 2061844 was isolated, is described. Preparation and sequencing of cDNAs in libraries in the LIFESEQ.TM. database have varied over time, and the gradual changes involved use of kits, plasmids, and machinery available at the particular time the library was made and analyzed.
I. OVARNOT03 cDNA Library Construction